BlossomHill Therapeutics has presented initial clinical data from its ongoing Phase 1/1b dose-escalation trial of BH-30236, a novel macrocyclic CLK (CDC-like kinase) inhibitor, at the European Hematology Association (EHA) 2026 congress. The compound demonstrated preliminary anti-leukemic activity in patients with relapsed or refractory acute myeloid leukemia (R/R AML) or high-risk myelodysplastic syndrome (HR-MDS), including individuals who had previously received venetoclax-based regimens — a population with historically limited therapeutic options.
BH-30236 was reported to be generally well tolerated across the dose cohorts evaluated, with pharmacokinetic profiling indicating favorable drug exposure characteristics. CLK kinases play a role in regulating pre-mRNA splicing, a process increasingly implicated in hematologic malignancies. Macrocyclic scaffolds are of growing interest in oncology drug design for their capacity to engage difficult target geometries with improved selectivity, though full dose, schedule, and response-rate data from this trial have not yet been published in a peer-reviewed format.
The hematologic oncology pipeline remains a high-priority segment for clinical-stage biotechs, with venetoclax resistance representing a significant unmet need in AML management. Early-phase tolerability signals in venetoclax-pretreated patients, if borne out in expanded cohorts, could position BH-30236 as a potential combination or sequencing candidate in future Phase 2 investigations. The EHA platform provides visibility to a broad base of European and global hematology specialists who influence both trial enrollment and eventual adoption decisions.
BlossomHill Therapeutics has not yet disclosed partnering or licensing arrangements tied to BH-30236. As the dose-escalation phase continues, the company is expected to identify a recommended Phase 2 dose and further characterize the compound's safety and efficacy profile. Investors and collaborators in the precision oncology space will be watching subsequent data readouts closely, particularly any expansion cohort results stratified by prior therapy and molecular subtype.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.